Description

Hansoh Pharmaceutical Group Company Limited functions as an investment holding enterprise primarily engaged in the full spectrum of pharmaceutical operations—from scientific inquiry and product innovation to manufacturing and commercialization—within the People's Republic of China. Its diverse array of medications targets significant therapeutic categories, including neurological disorders, oncological conditions, anti-infective treatments, and metabolic ailments. The company's prominent offerings encompass drugs like Mailingda, prescribed for chronic myelogenous leukemia, as well as a broad portfolio that includes Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote. Hansoh serves a client base predominantly consisting of pharmaceutical product distributors. Expanding its therapeutic reach, the company has established several strategic partnerships. It collaborates with Scynexis, Inc. on the advancement and market introduction of ibrexafungerp for vaginal yeast infections. Another alliance with Keros focuses on the development, production, and sales of KER-050, intended for treating cytopenias, anemia, and thrombocytopenia. Additionally, Hansoh is working with Olix Pharmaceuticals to identify and develop drug candidates for cardiovascular, metabolic, and liver-related diseases. A strategic pact with Silence Therapeutics plc is also in place to create siRNAs for three specific targets, utilizing Silence's proprietary mRNAi GOLD platform. Established in 1995, Hansoh Pharmaceutical Group Company Limited maintains its primary office in Lianyungang, People's Republic of China, and operates as a subsidiary of Stellar Infinity Company Ltd.